All Open NCCTG Studies (Jul 2, 2009)

Cancer Therapy Studies

Site Protocol Description
Breast N083E Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer
Breast N0733 Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive, Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
Breast N0735 Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer
CNS N0177 A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme
CNS N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
CNS N0572 A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma
CNS N0574 A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases - pre registration
CNS N057K Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma
CNS N0776 Phase II Trial of Avastin in Combination with Sorafenib in Recurrent Glioblastoma Multiforme
CNS N0779 Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme
CNS N0877 Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
CNS N027D A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme
GI N0147 A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
GI N054C Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer
GI N0745 Phase I/II Randomized Study of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma
GI N064A Phase II Study of Panitumumab, Chemotherapy and External Beam Radiation in Patients with Locally Advanced Pancreatic Cancer
GI N064B Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma
GI N0543 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Hematology N0682 A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma
Hematology N078D Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Hematology N078D Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Lung N0724 A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Systemic Therapy plus Either Radiotherapy to all Sites of Gross Disease or No Radiotherapy
Lung N0321 Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)
Lung N0626 A Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Lung N0723 MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Lung N0724 A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Systemic Therapy plus Either Radiotherapy to all Sites of Gross Disease or No Radiotherapy
Lung N0821 A phase II first-line study of a combination of pemetrexed, carboplatin and bevacizumab in advanced nonsquamous NSCLC eveluating efficacy and tolerability in elderly patients (age >/=70 yrs) with good performance status (PS <2)
Melanoma N0275 Phase II Trial Evaluating Resection Followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma
Melanoma N0775 A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin or ABI-007/Carboplatin (CBDCA) and Avastin in Patients with Unresectable Stage IV Malignant Melanoma

Cancer Control/Prevention Studies

Site Protocol Description
Multiple N08C1 Paclitaxel-Associated Acute Pain Syndrome Natural History Study
Other N04C2 An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot ) for Symptomatic Ascites in Cancer Patients
Other N06CA The Use of Topical Baclofen, Amitriptyline HCl, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Other N07C2 The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Other N08C1 Paclitaxel-Associated Acute Pain Syndrome Natural History Study
Other N08C3 Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy

Ancillary Studies

Site Protocol Description
CNS 947252 Diagnostic and Prognostic Markers in High-Grade Glioma
CNS 947253 Diagnostic and Prognostic Markers in Low-Grade Glioma
CNS 949452 Clinical Significance of Histologic Typing of High-Grade Glioma
CNS N0477 Optimizing EGFR Inhibitor-Based Therapies for GBM
Hematology N0682 A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma
Multiple N0392 Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials